C omplex traits such as height and weight are influenced by multiple genes and by environmental factors. Because of this complexity, genetic studies of these traits often involve hundreds of thousands of individuals. These studies typically focus on urban populations, for which large sample sizes are readily available. For example, the GIANT consortium recently reported 697 genetic variants that explain 20% of the heritability of adult height ( 1) , and 97 loci that account for just 2.7% of phenotypic variation in body mass index (BMI) ( 2) . These discoveries required a staggering 250,000 to 300,000 individuals in total. And yet, on page 1343 of this issue, Fumagalli et al. report the identification of genetic variants influencing height and BMI based on data from just a few thousand Inuit individuals ( 3) . These results exemplify how modern humans have adapted to diverse climates and diets.
The authors increase the statistical power for identifying genetic associations by first searching for targets of natural selection and then looking for association between those loci and potentially adaptive traits. Thus, they first identified genomic targets of natural selection in 191 individuals of Inuit ancestry residing in Greenland and then looked for an association of those regions with anthropometric and metabolic traits in a larger, but still modest, set of ~4500 Inuit individuals.
The Inuit population has inhabited the Arctic region for thousands of years, adapting to a cold climate and a diet rich in marine-derived fat. Using a single-nucleotide polymorphism (SNP) genotyping array designed to target metabolism-related genetic variants [the Metabochip ( 4) ] and exome sequencing of a subset of 18 individuals, Fumagalli et al. identified several variable genome regions that differ in frequency in the Inuit population compared to Europeans and Chinese, possibly due to long-standing selective pressures to adapt to the Arctic environment. Genes found in these regions include those that code for fatty acid desaturases (FADS, important modulators of fatty acid composition), in addition to genes that play a role in fat distribution and in muscle and heart development. Derived variants that were targets of selection near the FADS loci were associated with smaller body size and shorter stature in the Inuit cohort. Two of these variants were modestly associated with a decrease in height in a cohort of 170,000 Europeans. These variants had not been significantly associated with height or body size in the larger European cohort, possibly because of their low frequency in that population.
Fumagalli et al.'s study shows that inclusion of ethnically diverse populations that have adapted to extreme environments for thousands of years may be particularly informative for genetic studies of variable traits. The analysis of genetic variants in individuals with phenotypes at the extremes of the trait distribution has been successfully used to identify functionally relevant genetic variants within populations. For example, analysis of European-descent individuals with extremely low concentrations of low-density lipoprotein (LDL) cholesterol led to the identification of loss-of-function mutations in the gene coding for PCSK9, a key factor for lowering cholesterol ( 5) that is now the target of novel drug treatments ( 6) .
Adaptation to diverse environments during human evolution has resulted in populations with phenotypes that are at the extremes of the trait distribution across all humans. Extreme phenotypes resulting from natural selection may in some cases be due to relatively few genetic variants with large effect. Integration of scans for natural selection, to narrow down candidate loci, with phenotype association studies can be particularly informative for identifying genetic variants associated with complex traits, even in studies with small sample sizes. For example, this approach has been used to identify genetic loci influencing the extreme short stature trait in Central African huntergatherer populations, a trait thought to be an adaptation to a tropical environment ( 7, 8) . It has also been used to find loci influencing physiologic adaptation to high altitude in Tibet, South America, and Ethiopia ( 9) . These studies
Strength in small numbers
A small-scale genome study of an indigenous population elucidates the genetics that influence height and weight show that smaller-scale studies of ethnically diverse populations living in a range of different environments and experiencing local adaptation are important and complementary to large genome-wide association studies (GWAS) of urban populations (see the figure) . The study of indigenous populations can be informative for several reasons. For example, although environments may vary considerably between populations, the environments within individual populations are often relatively homogeneous (similar diets, cultural habits, and environmental exposures). This can improve the power to identify genetic factors influencing complex phenotypes. In addition, increased levels of inbreeding in some small indigenous populations lead to regions of the genome that are identical within and among individuals and that can be useful for identifying rare variants influencing complex traits ( 10) .
GENETICS
More fundamentally, investigation of such populations is crucial to further distribute the benefits of "precision medicine" and the associated development of targeted therapeutics. However, indigenous populations, particularly those living in rural areas with little access to health care, can be very challenging to study. Great care must be taken to avoid coercion and to be respectful of local practices, customs, and beliefs. This issue has been of particular concern to some Native American and Australian Aboriginal populations who may not want to participate in genomics research because of cultural beliefs. Some indigenous populations are also wary of genomics research owing to concerns about exploitation. There is valid concern about commercialization of information obtained from studies of indigenous populations. However, that concern must be balanced by the important need to develop therapeutics that will benefit all populations, not just those in developed countries. Thus, dialogue between researchers and indigenous communities is needed to ensure benefit sharing. It is critical to include diverse peoples in genomic studies to understand the phenotypic impact of the full range of human genetic variation and to ensure that all peoples benefit from this knowledge. ■ T he isolation and molecular characterization of circulating tumor cells (CTCs) to guide cancer therapy is a particularly attractive approach for men with metastatic prostate cancer where the primary tumor may have been removed years earlier and the only indication of disease progression may be a rising amount of prostate-specific antigen (PSA) in the blood and a worsening bone scan (the skeleton is commonly the first area of metastasis for this cancer). Consequently, numerous technologies to capture, isolate, and study prostate cancer CTCs have been developed, each with its own limitations. Because of CTC heterogeneity, isolation approaches that rely on cell surface protein expression may not identify the prostate cancer cells undergoing epithelial-to-mesenchymal transition (which contributes to the migratory capacity and invasiveness of CTCs) ( 1) . On page 1351 of this issue, Miyamoto et al. ( 2) report on the use of a microfluidic device that enables the capture of live CTCs amenable to single-cell molecular characterization ( 3) . The study reveals a possible mechanism underlying the resistance of certain prostate cancer patients to androgen-targeted therapies.
Prostate cancer growth is driven by male sex hormones called androgens, the most common of which is testosterone. Androgen deprivation therapy therefore remains the most effective treatment for patients with metastatic "castration-sensitive" prostate cancer. This is commonly accomplished through medical castration with drugs that inhibit testosterone production. For many men with "castration-resistant" prostate cancer, therapy frequently involves newer agents such as abiraterone (an androgen synthesis inhibitor) and enzalutamide [an androgen receptor (AR) antagonist or "antiandrogen"]. Retrospective studies examining prostate cancer CTCs that sought to decipher resistance to androgen signaling-targeted therapies ( 4, 5) have directly led to larger prospective studies using multiple CTC isolation technologies to identify biomarkers of sensitivity and resistance to abiraterone and enzalutamide, including splice variants of AR-encoding messenger RNA (mRNA).
Miyamoto et al. used an antigen-agnostic microfluidic device called CTC-iChip ( 3) (see the first figure) to characterize gene expression in 77 single CTCs isolated from 13 patients with prostate cancer, of whom 11 had castration-resistant prostate cancer. The single-CTC RNA sequencing results provide several important observations that would not have been "resolved" in population-averaging RNA sequencing analyses. Single-CTC analysis showed that only one-sixth of the CTCs co-expressed more than one AR splice variant (AR-V), which is in sharp contrast to
